A carregar...
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
BACKGROUND: Systemic sclerosis (SSc) is a clinically heterogeneous, life-threatening disease characterized by fibrosis, microvasculopathy, and autoimmunity. Extensive nonclinical and clinical data implicate B cells in the pathogenesis of SSc. MEDI-551 is an investigational humanized monoclonal antib...
Na minha lista:
Publicado no: | Arthritis Res Ther |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4895815/ https://ncbi.nlm.nih.gov/pubmed/27267753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1021-2 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|